

## **SUMMARY OF STUDY ON “SINUS ALLERGY RELIEF” CHIP BY CIEAURA**

Randomized, Double-Blind, Placebo-Controlled Study  
Of the Effects of Non-transdermal, CieAura Transparent Holographic  
“Sinus Allergy Relief” Chip Application for the Reduction of Sinus and  
Allergy Symptoms

### **OBJECTIVE:**

The objective of this study is to test whether the CieAura Transparent Holographic Sinus Allergy Relief Chip reduces sinus and allergy symptoms in those subjects who properly use it.

### **METHODS:**

68 participants, all of whom have sinus or allergy discomfort, were randomized into Group A or B. Two packets of identical appearance holographic chips, “Sinus Allergy Relief”, were sent by CieAura, also labeled “A” or “B”. One packet of chips was “charged” or active, and the other was “uncharged” or placebo. Neither the examiner nor the participants were aware of which group of chips were “charged” or placebo. Chips were initially placed on participants by the investigator, always on a Monday. The chip was placed behind the right ear, and participants were then given 2 additional chips with instructions to replace the chip on Wednesday and Friday. They were instructed to alternate ears every 2 days with chip placement. They were also counseled on proper storage of chips and the importance of hydration. They were also instructed not to take any other medications or supplements for cold, congestion, etc. for 1 week. Participants were then seen again on the following Monday. Participants rated their level of sinus discomfort from 1-10 prior to chip placement, and then again at the 1 week follow up.

### **RESULTS:**

Of the 68 participants, 34 were randomized to Group A and 34 were randomized to Group B.

The 34 participants in Group A were reduced to 20 by the end of the week due to lack of follow up or failure to continue chip use throughout the week. Of the 20 participants in Group A, 2 rated a

significant improvement in their sinus symptoms (9%) and 18 rated no significant difference (91%).

The 34 participants in Group B were reduced to 25, again due to lack of follow up or failure to continue chip use throughout the week. Of the 25 participants in Group B, 23 rated a significant improvement in their sinus symptoms (93%) and 2 rated no significant difference (7%).

#### INTERPRETATION/SUMMARY:

After the data collection, Group B was revealed to be the “charged” packet of chips. This group showed a 93% success rate in symptom relief with chip placement. In contrast, the participants in Group A only showed a 9% success rate, which is consistent with the accepted range of placebo effect. 91% of Group A participants had no relief of symptoms. This is a statistically significant difference and therefore supports the theory that the CieAura Transparent Holographic Sinus Allergy Relief Chips do, in fact, reduce sinus symptoms in those subjects who properly use it.